Physician profile
Gerald Andriole
NPI 1295752723
$64,000.80
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $12K · 2021: $9,859 · 2022: $9,994 · 2023: $18K · 2024: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $2,235 · Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,500.00 |
| Travel and Lodging | $2,234.64 |
| Food and Beverage | $487.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26,364.21 | 2019-2022 | |
| Blue Earth Diagnostics | $7,662.58 | 2019-2021 | |
| Quest Medical INC. | $6,000.00 | 2023 | |
| Progenics Pharmaceuticals, INC. | $5,280.87 | 2021-2024 | Pylarify |
| Siemens Medical Solutions USA, INC. | $4,880.98 | 2023 | |
| Merck Sharp & Dohme LLC | $3,500.00 | 2019-2024 | |
| Clovis Oncology, INC. | $3,431.25 | 2019 | |
| Janssen Scientific Affairs, LLC | $3,167.38 | 2019-2021 | |
| Edap Technomed INC | $3,000.00 | 2023 | |
| Pfizer INC. | $347.85 | 2019-2023 | |
| Photocure INC | $169.03 | 2019 | |
| Janssen Biotech, INC. | $71.71 | 2023 | Erleada |
| Astellas Pharma US INC | $70.38 | 2019 | |
| Angiodynamics, INC. | $27.69 | 2022 | |
| Tolmar, INC. | $26.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Andriole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.